Recurrent Breast Cancer Recruiting Phase 1 Trials for Pertuzumab (DB06366)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

DBCOND0028640 (Recurrent Breast Cancer)Recruiting1 IdentifierTitlePurposeDrugs
NCT02390427Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerTreatment